Background-A school-based electrocardiographic screening program has been developed in Japan. However, few data are available on the genetic characteristics of pediatric patients with long-QT syndrome who were diagnosed by this program. Methods and Results-A total of 117 unrelated probands aged ≤18 years were the subjects who were referred to our centers for genetic testing. Of these, 69 subjects diagnosed by the program formed the screened group. A total of 48 subjects were included in the clinical group and were diagnosed with long-QT syndrome-related symptoms, familial study, or by chance. Mutations were classified as radical, of high probability of pathogenicity, or of uncertain significance. Two subjects in the clinical group died. Genotypes were identified in 50 (72%) and 23 (48%) of subjects in the screened and clinical groups, respectively. Of the KCNQ1 or KCNH2 mutations, 31 of 33 (94%) in the screened group and 14 of 15 (93%) in the clinical group were radical and of high probability of pathogenicity. Prevalence of symptoms before (9/69 versus 31/48; P<0.0001) and after (12/69 versus 17/48; P=0.03) diagnosis was significantly lower in the screened group when compared with that in the clinical group although the QTc values, family history of long-QT syndrome, sudden death, and follow-up periods were not different between the groups. Conclusions-These data suggest that the screening program may be effective for early diagnosis of long-QT syndrome that may allow intervention before symptoms. In addition, screened patients should have follow-up equivalent to clinically identified patients. (Circ Arrhythm Electrophysiol. 2014;7:107-112.)
C ongenital long-QT syndrome (LQTS) is a genetic disorder characterized by delayed repolarization and by a long-QT interval on 12-lead ECGs. Although many patients do not have symptoms, the hallmark of the condition is syncope or sudden death because of torsade de pointes. 1, 2 To date, 13 genes have been identified. 3, 4 There have been many reports on the clinical and genetic backgrounds of patients with LQTS. However, these were mainly based on data collected from patients who had LQTS-related symptoms or familial studies and from combined adult and pediatric populations. 2, [5] [6] [7] [8] [9] 
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A nationwide school-based ECG screening program for heart diseases in first, seventh, and 10th graders in Japan has revealed children and adolescents with prolonged QT intervals. The prevalence of subjects with prolonged QT intervals was ≈1:1200 in the seventh grade. 10 Differences in clinical characteristics between patients who were screened by the program and those who visited hospitals with symptoms have been previously reported. 11 However, before this study, few data have been reported about the genetic characteristics of pediatric patients who were diagnosed by ECG screening programs and whose genetic testing was performed. [12] [13] [14] In addition, because of a lack of reports containing large numbers of patients who were screened alongside genetic testing, it is unclear whether screened subjects have similar mutations of a high possibility of pathogenesis to those who have LQTS-related symptoms.
From the genetic testing viewpoint, the few percentage background rate of the rare KCNQ1 and KCNH2 nonsynonymous single nucleotide variants among healthy individuals has lessened the ability to distinguish rare pathogenic mutations from similarly rare, yet presumably innocuous, variants. 15, 16 Novel mutations have been found in every study, 17, 18 but it is difficult to perform electrophysiological studies for February 2014 each novel mutation except in large laboratories. Recently, an algorithm designed to guide the interpretation of genetic testing results for KCNQ1 and KCNH2 has been developed. 16 Thus, the aim of the present study was to determine the genetic characteristics of pediatric patients with LQTS who were diagnosed by a school-based screening program and whose genetic testing was performed and to compare results with subjects who visited hospitals because of the presence of LQTS-related symptoms, familial history, or who were diagnosed by chance.
Methods

Study Population
The study population included 117 unrelated probands ≤18 years of age who were referred to the Department of Pediatrics, Kagoshima University Hospital, Japan, between November 1993 and March 2005 or to the National Hospital Organization Kagoshima Medical Center from April 2005 to December 2012 for genetic evaluation. The population included 69 subjects who were screened by a school-based ECG screening program (Table 1 ). In the present study, LQTS-related symptoms were defined as syncope, aborted cardiac arrest, or sudden cardiac death at <30 years old. Subjects were divided into 2 groups on the basis of index events: subjects who were diagnosed by the schoolbased ECG screening program (screened group) and those who visited hospitals because of the presence of symptoms and family history or who were diagnosed by chance (clinical group; Table 1 ).
Diagnosis of LQTS and Screening of QT Intervals in the School-based ECG Screening Program
The present study was a retrospective study, and diagnosis of LQTS and screening for prolonged QT intervals was based on the judgment of the chief medical doctors in each hospital or doctors who participated in the program in each area. Many Japanese cardiologists use a scoring system published in 1993 19 and recently 1 for the final diagnosis of LQTS. To screen subjects with prolonged QT intervals in the program, the Japanese Society of Pediatric Cardiology and Cardiac Surgery recommended that children and adolescents be screened when they have a QTc value, using Bazett formula, of ≥450 ms at a heart rate of <75 beats per minute or a QTc≥500 ms at a hours of ≥75 beats per minute. 20 Bazett formula overcorrects the QT interval at high heart rates. Pediatric cardiologists who participated in the program used age-and sex-specific criteria using an exponential formula (QT/RR 0.31 ) 21 or Fridericia formula. 22 In the screening program, cardiologists use computer-based QTc values as a reference because all ECG machines used in Japan are generally equipped with a function for automated measurement of QT intervals. However, manual measurement using the tangent method is usually applied to obtain QT intervals in Japan. 22, 23 
Genetic Testing
Referral for genetic testing was based on the opinion of the chief medical doctors in the present study. Pediatric cardiologists in the present study recommended genetic testing based on the following criteria: (1) for a patient in whom they had established a strong clinical index of suspicion for LQTS based on examination of the patient's clinical history, family history, and expressed ECG phenotype or; (2) for an asymptomatic patient with QT prolongation in the absence of other clinical conditions that might prolong the QT interval, as detailed in the recent consensus recommendation report. 24 Genomic DNA was isolated from blood after obtaining written informed consent. Genetic screening for all exons of KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, and CAV3 was reperformed for the present study using polymerase chain reaction and direct DNA sequencing. When a patient was suspected to have Timothy syndrome, which is a multisystem disorder characterized by cardiac (QT prolongation and sometimes congenital heart diseases), hand/foot, facial, and neurodevelopmental features, the exons of CACNA1C were amplified. When a patient had a prolonged QT interval and hyperaldosteronism, the exon of KCNJ5 was amplified. The exons of ANKB, SCN4B, AKAP9, and SNTA1 were not analyzed because of a lack of reported cases of these mutations in the Japanese population. Genomic DNA was isolated using a QIAamp DNA Blood Midi Kit (Qiagen, Gaithersburg, MD). Polymerase chain reaction products were purified using AMPure (Beckman Coulter, Brea, CA). After treating with BigDye Terminator version 1.1 Cycle Sequence Kit (ABI, Warrington, United Kingdom) and BigDye X Terminator, direct sequencing was performed by a genetic analyzer, ABI3130x1 Genetic Analyzer (ABI). The study was approved by the Ethics Committee of the Kagoshima University Hospital between November 1993 and March 2005 and the National Hospital Organization Kagoshima Medical Center from April 2005.
Nucleotide changes reported as single nucleotide polymorphisms 18, 25 were excluded from mutation analysis in the present study. However, amino acid changes of G643S in KCNQ1 26 and D85N in KCNE1 27 were included in the present study because previous reports have shown that these mutations are associated with an ≈30% reduction in potassium channel currents. 26, 27 When multiple mutations were present, each mutation was counted in each genotype.
Mutations of High Probability of Pathogenicity
Mutations of a high probability of pathogenicity were based on data published by Giudicessi et al. 16 Radical mutations included splicesite, nonsense, frame-shift, and insertion/deletions. 16 Mutations of a high probability of pathogenicity in the present study were defined as those present in the subunit assembly domain of the C-terminal of KCNQ1, the Per-Arnt-Sim domain, Per-Arnt-Sim-associated C-terminal domain, and the cyclic nucleotide-binding domain of KCNH2. Mutations present in the transmembrane/linker/pore and C-terminal regions of KCNQ1 and the transmembrane/linker/pore regions of KCNH2 were also defined as those of a high probability of pathogenicity. 16 Remaining mutations were defined as those of uncertain significance. 
Statistical Analysis
Differences in the mean values and prevalence values were examined using the Mann-Whitney U test and Fisher exact probability test, respectively. Tukey multiple comparison test was used to assess differences in the mean QTc values among first, seventh, and 10th graders. Statistical analysis was performed using IBM SPSS Statistics version 21.0 (IBM Japan, Ltd, Tokyo, Japan). A 2-tailed P value of <0.05 was considered statistically significant.
Results
Population
Characteristics of the 117 subjects, including 69 screened and 48 clinical patients, are shown in Table 1 . Of the 48 subjects included in the clinical group, 36 were diagnosed with LQTSrelated symptoms, 6 were diagnosed by familial study, and 6 were diagnosed by chance. Subjects who were diagnosed by chance included those who visited hospitals for medical checks and for examination of heart murmurs at 1 month (4 patients), those who had been followed with Kawasaki disease (1 patient), and as Ehlers-Donlos syndrome (1 patient). There were no differences in sex, mean QTc values, family history of LQTS, family history of sudden death, or follow-up period between the screened and clinical groups. The mean age was lower in the clinical group when compared with the screened group (P=0.04). Prevalence of subjects having LQTS-related symptoms before and after diagnosis was significantly lower in the screened group when compared with that in the clinical group (P<0.001 and P=0.03, respectively). Symptoms before and after diagnosis in the screened group were all syncope. Of 117 subjects, 2 subjects in the clinical group died. A girl had a history of aborted cardiac arrest at 2 months, and died suddenly in her sleep at 5 years of age. An 11-year-old boy had frequent symptoms and died suddenly during class. Genetic analysis failed to show the presence of any of the mutations analyzed in this study. The treatment of subjects with symptoms during follow-up period is shown in Table I in the onlineonly Data Supplement.
Mutations Determined in the Present Study
The yield of genetic testing in the present study by QTc values using Bazett formula is shown in Table II in the Data Supplement. The data show that there was no difference in yield between subjects with a QTc<500 ms and those with a QTc≥500 ms in both screened and clinical groups in the present study. Of 50 subjects who were screened and whose mutations were identified, 29, 18, and 3 subjects were screened in the first, seventh, and 10th grade, respectively. Their QTc values using Bazett formula were 491±35, 503±43, and 500±49 ms, respectively. There were no differences in QTc values among the screened periods. Of 117 subjects, mutations were found in 50 of 69 (72%) screened and 23 of 48 (48%) clinical subjects ( Table III in the Data Supplement). The prevalence of LQT1, LQT2, and LQT3 between the 2 groups was not different. LQTS-related mutations in the present study are summarized in Table IV in the Data Supplement.
Genetic Characteristics of Subjects
All mutations found in KCNQ1 from 18 mutations in the screened and 9 mutations in the clinical groups were located in regions of a high probability of pathogenicity (Table 2 ; Figure 1A and 1B). In the screened group, 8 mutations were located in the transmembrane/linker/pore regions and 10 were present in the C-terminal regions ( Figure 1A ). Three mutations were radical and 1 mutation was present in the subunit assembly domain. About the association between locations of mutation and the presence or absence of LQTS-related symptoms, 14 (78%) of 18 mutations were associated with the presence of symptoms in probands and family members, including 4 (22%) with family history of sudden death in the screened group. Eight of 9 mutations in the clinical group were associated with the presence of symptoms, and the remaining mutation was found in a subject who was diagnosed by a familial study.
Among mutations yielded in KCNH2, 13 (87%) of 15 mutations in the screened group and 5 (83%) of 6 mutations in the clinical group were located in regions of a high probability of pathogenicity ( Table 2 ; Figure 2A and 2B) . In the screened group, 1 mutation was both radical and present in the cyclic nucleotide-binding domain. Another 5 mutations were radical, and 1 each was present in Per-Arnt-Sim and Per-Arnt-Sim-associated C-terminal regions. However, only 4 (31%) of 13 mutations were associated with the presence of LQTSrelated symptoms in probands or family members in the screened group. In the clinical group, 5 (83%) of 6 mutations were associated with the presence of symptoms in probands and family members, and the remaining mutation was found in a subject by ECG screening during a medical check-up at 1 month.
Discussion
Mutations in subjects with LQTS who were diagnosed by school-based ECG screening programs were mostly of high possibility of pathogenicity, similar to clinical subjects. Clinical background, such as QTc values, family history of LQTS, or sudden death, and follow-up periods, was not different between the 2 groups. However, prevalence of symptoms before and after diagnosis in the screened group was significantly lower when compared with the clinical group. †Radical mutations include splice-site, nonsense, frame-shift, and insertion/ deletions. ‡Mutations of high probability include subunit assembly domain, transmembrane/linker/pore, and C-terminal regions of KCNQ1, and the Per-Arnt-Sim (PAS) domain, PAS-associated C-terminal domain, the cyclic nucleotide-binding domain, transmembrane/linker/pore region of KCNH2. February 2014
These data suggest that screening programs may be effective for early diagnosis of LQTS and prevention of symptoms, and that screened patients should be followed similar to clinical patients.
Clinical and genetic backgrounds of patients with LQTS have been reported widely for infants, children, adolescents, and adults. [5] [6] [7] [8] [9] These data were mostly based on symptomatic probands and family members. Few data are available on the genetic background of subjects who were diagnosed by ECG screening programs. Schwartz et al 12 reported that LQTS-related mutations were identified in 16 neonates of 43 080 who underwent neonatal ECG screening; 8 KCNQ1, 5 KCNH2, and 1 each of KCNE1 and KCNE2. One infant had a digenic mutation of KCNQ1 and KCNH2.
A school-based ECG screening program for heart diseases was initiated in 1994 for first, seventh, and 10th graders in Japan. The program screened subjects with QT prolongation. However, few studies have confirmed the genetic background in these screened subjects. 13, 14 Hayashi et al 13 reported that mutations were identified in 3 subjects with high or intermediate probabilities of LQTS using Schwartz criteria from 7961 school children; all 3 mutations were present in KCNH2. Yasuda et al 14 reported that KCNQ1 mutations were found in 8 of 13 pediatric patients and that 7 of 8 patients were diagnosed by the ECG screening program.
In the present study, a relatively large number of subjects, who were diagnosed by ECG screening programs accompanied by genetic testing, were included. The clinical backgrounds of the screened subjects, such as QTc values, family history of LQTS, or sudden death, were similar to clinical subjects. All 16 mutations in the KCNQ1 gene in the screened group were radical or of high probability of pathogenicity similar to the clinical group. The ratio of mutations of radical and of high probability of pathogenicity in the KCNH2 gene in the screened group (13/15; 87%) was remarkably similar to that in the clinical group (5/6; 83%). These data suggest that pediatricians, who asked for genetic testing in the present study, chose patients with similar clinical backgrounds in both groups, and that demand for genetic testing was more prevalent in screened patients when compared with clinical patients when ECG screening was developed in Japan.
Conversely, prevalence of symptoms before and after diagnosis was significantly lower in the screened group when compared with that in the clinical group. A low prevalence of symptoms before diagnosis suggests that the ECG screening program is effective for early diagnosis of LQTS. The reason for low prevalence of symptoms after diagnosis in the screened group is uncertain. Doctors may recommend pediatric patients with LQTS and their parents adopt changes to their lifestyles, for example, not doing vigorous exercise, not swimming a lap, and not diving, 28 in both the screened and clinical subjects. The precise reason remains to be clarified.
The reason for no difference in the prevalence of family history between the screened and clinical groups is unclear. The authors posit that even now in Japan the general population may not be familiar with LQTS, and that the parents in the present study did not think that syncope in their children was a serious condition. In addition, they may have been unaware that LQTS is an inherited disease. The reason of the high prevalence of family history of LQTS in the screened group is also unclear. The authors speculate that doctors did not ask the parents (grandparents of the probands in the present study) to perform familial studies 2 or 3 decades ago, when parents of the probands of the present study and their family members experienced symptoms at younger ages; however, no data were obtained addressing this hypothesis from the families.
There are some limitations of the current study. First, we did not discuss subjects with the SCN5A gene. One fourth of pediatric patients with LQTS had the SCN5A gene. We need similar algorithms designed to guide the interpretation of genetic testing results for the SCN5A mutation and to determine the possibility of pathogenesis in patients with SCN5A in the future. Second, the clinical group showed a low rate (48%) of genotypic determination. We could not find mutations in 2 cases of death in the present study. The reasons for this are unclear. One potential reason was that we did not screen copy number variations in genes associated with LQTS. 29, 30 Eddy et al 29 and Barc et al 30 reported that 3 of 26 (12%) and 3 of 93 (3%) unrelated mutation-negative probands showed copy number variations, indicating that some mutation-negative patients may have copy number variations. Another reason may be that numerous previously undetected mutations exist in symptomatic patients.
In conclusion, mutations in subjects with LQTS who were diagnosed by screening programs had a high probability of pathogenicity similar to clinical subjects. Clinical backgrounds were not different although the prevalence of symptoms before and after diagnosis in the screened group was significantly lower when compared with that in the clinical group. These data suggest that the school-based screening program may be effective for early diagnosis of LQTS and prevention of symptoms, and that screened patients should have follow-up equivalent to clinical patients. 
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